Shares of Alexion Pharamaceuticals (ALXN) register a gain after the firm says it has received a positive opinion in Europe for Soliris with a final decision from the European Commission expected in about two months. Soliris is a first treatment for patients with a rare life-threatening blood disorder.
ALXN is up 2.14 to 65.52
Alexion is the Number 1 rated stock in Investor's Business Daily's Top 50.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment